Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s full-year guidance.
Commentary|Podcasts|December 22, 2025
Scaling Sustainability: A Big Pharma Formula
Author(s)Michael Christel
Jim Greffet, head of sustainability at Eli Lilly, on establishing ESG as a core business driver—and key complement to manufacturer long-term growth pursuits.
Advertisement
In this podcast conversation with Pharm Exec, Jim Greffet, VP of sustainability at Eli Lilly, unpacks how environmental, social, and governance (ESG) goals are shaping the organization’s next phase of growth—particularly as demand surges for its GLP-1 products Zepbound and Mounjaro. From access and affordability to supply chain expansion and climate commitments, Greffet shares the importance of embedding long-term thinking into operational strategy, which for Lilly includes the company's quest to reach 30 million patients in resource-limited settings by 2030, among other ESG goals.
Highlights of Greffet's discussion with Michael Christel, MJH Life Sciences Group Managing Editor, include:
- Why Zepbound/the obesity space has made access a defining sustainability issue
- Building future-ready supply chains while cutting emissions and energy use
- Data-driven measures and accountability — “numbers are your friends”
- Sustainability as “sensible business practice,” not distraction from core mission
- And more!
Advertisement
Related to this article
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, adding non-opioid pain therapies Exparel and Zilretta.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Advertisement
Advertisement
Trending on PharmExec
1
Bausch + Lomb Appoints Thomas Appio as Interim CEO
2
The Manufacturing Issues That Continue to Contribute to Drug Shortages
3
AI and the Apprenticeship Gap: Rethinking Work for Experienced and Early-Career Talent in Professional Services
4
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
5